Article
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
Molecular cancer therapeutics - 1 Aug 2013
Nadiminty Nagalakshmi, Tummala Ramakumar, Liu Chengfei, Yang Joy, Lou Wei, Evans Christopher P, Gao Allen C
Abstract excerpt
Resistance of prostate cancer cells to the next-generation antiandrogen enzalutamide may be mediated by a multitude of survival signaling pathways. In this study, we tested whether increased expression of NF-κB2/p52 induces prostate cancer cell resistance to enzalutamide and whether this response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
